Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
The submission is supported by results from the Phase 3b APEX study
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Subscribe To Our Newsletter & Stay Updated